Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Unveiling the Multifaceted Roles of ISG15: From Immunomodulation to Therapeutic Frontiers

  • Álvarez, Enrique
  • Falqui, Michela
  • Sin, Laura
  • McGrail, Joseph Patrick
  • Perdiguero, Beatriz
  • Coloma, Rocío
  • Marcos-Villar, Laura
  • Tárrega, Céline
  • Esteban, Mariano
  • Gómez, Carmen E.
  • Guerra, Susana
The Interferon Stimulated Gene 15 (ISG15), a unique Ubiquitin-like (Ubl) modifier exclusive to vertebrates, plays a crucial role in the immune system. Primarily induced by interferon (IFN) type I, ISG15 functions through diverse mechanisms: (i) covalent protein modification (ISGylation); (ii) non-covalent intracellular action; and (iii) exerting extracellular cytokine activity. These various roles highlight its versatility in influencing numerous cellular pathways, encompassing DNA damage response, autophagy, antiviral response, and cancer-related processes, among others. The well-established antiviral effects of ISGylation contrast with its intriguing dual role in cancer, exhibiting both suppressive and promoting effects depending on the tumour type. The multifaceted functions of ISG15 extend beyond intracellular processes to extracellular cytokine signalling, influencing immune response, chemotaxis, and anti-tumour effects. Moreover, ISG15 emerges as a promising adjuvant in vaccine development, enhancing immune responses against viral antigens and demonstrating efficacy in cancer models. As a therapeutic target in cancer treatment, ISG15 exhibits a double-edged nature, promoting or suppressing oncogenesis depending on the tumour context. This review aims to contribute to future studies exploring the role of ISG15 in immune modulation and cancer therapy, potentially paving the way for the development of novel therapeutic interventions, vaccine development, and precision medicine., This research was supported by Spanish Ministry of Science and Innovation (MCIN)/Spanish State Research Agency, state secretary of R + D and FEDER/FSE grants: SAF2017-88089-R and PDC2021-121307-I00 to S.G. and M.E., PID2020-117425RB-C21 to S.G. and PID2020-117425RB-C22 to C.E.G., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

An MVA-based vector expressing cell-free ISG15 increases IFN-I production and improves HIV-1-specific CD8 T cell immune responses

  • Falqui, Michela
  • Perdiguero, Beatriz
  • Coloma, Rocío
  • Albert, Manuel
  • Marcos-Villar, Laura
  • McGrail, Joseph Patrick
  • Sorzano, Carlos Óscar S.
  • Esteban, Mariano
  • Gómez, Carmen Elena
  • Guerra, Susana
The human immunodeficiency virus (HIV), responsible of the Acquired Immune Deficiency Syndrome (AIDS), continues to be a major global public health issue with any cure or vaccine available. The Interferon-stimulated gene 15 (ISG15) encodes a ubiquitin-like protein that is induced by interferons and plays a critical role in the immune response. ISG15 is a modifier protein that covalently binds to its targets via a reversible bond, a process known as ISGylation, which is the best-characterized activity of this protein to date. However, ISG15 can also interact with intracellular proteins via non-covalent binding or act as a cytokine in the extracellular space after secretion. In previous studies we proved the adjuvant effect of ISG15 when delivered by a DNA-vector in heterologous prime-boost combination with a Modified Vaccinia virus Ankara (MVA)-based recombinant virus expressing HIV-1 antigens Env/Gag-Pol-Nef (MVA-B). Here we extended these results evaluating the adjuvant effect of ISG15 when expressed by an MVA vector. For this, we generated and characterized two novel MVA recombinants expressing different forms of ISG15, the wild-type ISG15GG (able to perform ISGylation) or the mutated ISG15AA (unable to perform ISGylation). In mice immunized with the heterologous DNA prime/MVA boost regimen, the expression of the mutant ISG15AA from MVA-Δ3-ISG15AA vector in combination with MVA-B induced an increase in the magnitude and quality of HIV-1-specific CD8 T cells as well as in the levels of IFN-I released, providing a better immunostimulatory activity than the wild-type ISG15GG. Our results confirm the importance of ISG15 as an immune adjuvant in the vaccine field and highlights its role as a potential relevant component in HIV-1 immunization protocols., This research was supported by the Spanish State Research Agency Ministry of Health of Spain, State secretary of R+D and FEDER/FSE, SAF-2017-88089-R, PDC2021-121307-I00 PID2020- 117425RB-C21 to SG and PID2020-117425RB-C22 to CG; by CIBER consortium, Thematic Area in Infectious Diseases: CIBERINFEC (CB21/13/00108) to CG; by Red Temática de Investigación Cooperativa en Salud: Red Española de Investigación en Sida (RIS) RD16/0025/0014 and in part by European HIV Vaccine Alliance (EHVA) grant ID: 681032 to ME., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

B and T Cell Bi-Cistronic Multiepitopic Vaccine Induces Broad Immunogenicity and Provides Protection Against SARS-CoV-2

  • Perdiguero, Beatriz
  • Álvarez, Enrique
  • Marcos-Villar, Laura
  • Sin, Laura
  • López-Bravo, María
  • Valverde, José Ramón
  • Sorzano, Carlos Óscar S.
  • Falqui, Michela
  • Coloma, Rocío
  • Esteban, Mariano
  • Guerra, Susana
  • Gómez, Carmen E.
[Background]: The COVID-19 pandemic, caused by SARS-CoV-2, has highlighted the need for vaccines targeting both neutralizing antibodies (NAbs) and long-lasting cross-reactive T cells covering multiple viral proteins to provide broad and durable protection against emerging variants., [Methods]: To address this, here we developed two vaccine candidates, namely (i) DNA-CoV2-TMEP, expressing the multiepitopic CoV2-TMEP protein containing immunodominant and conserved T cell regions from SARS-CoV-2 structural proteins, and (ii) MVA-CoV2-B2AT, encoding a bi-cistronic multiepitopic construct that combines conserved B and T cell overlapping regions from SARS-CoV-2 structural proteins., [Results]: Both candidates were assessed in vitro and in vivo demonstrating their ability to induce robust immune responses. In C57BL/6 mice, DNA-CoV2-TMEP enhanced the recruitment of innate immune cells and stimulated SARS-CoV-2-specific polyfunctional T cells targeting multiple viral proteins. MVA-CoV2-B2AT elicited NAbs against various SARS-CoV-2 variants of concern (VoCs) and reduced viral replication and viral yields against the Beta variant in susceptible K18-hACE2 mice. The combination of MVA-CoV2-B2AT with a mutated ISG15 form as an adjuvant further increased the magnitude, breadth and polyfunctional profile of the response., [Conclusion]: These findings underscore the potential of these multiepitopic proteins when expressed from DNA or MVA vectors to provide protection against SARS-CoV-2 and its variants, supporting their further development as next-generation COVID-19 vaccines., This research was supported by La Caixa Banking Foundation, grant CF01-00008; Spanish Ministry of Science and Innovation (MCIN)/Spanish Research Agency, grants PID2020-117425RB-C21, PID2020-117425RB-C22 and PDC2021-121307-100; Fondo COVID-19, grant COV20/00151 (Spanish Health Ministry and ISCIII); CSIC, grant 2020E84; and Ferrovial donations (to M.E.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

ISG15 as a Potent Immune Adjuvant in MVA-Based Vaccines Against Zika Virus and SARS-CoV-2

  • García-Arriaza, Juan
  • Falqui, Michela
  • Pérez, Patricia
  • Coloma, Rocío
  • Perdiguero, Beatriz
  • Álvarez, Enrique
  • Marcos-Villar, Laura
  • Astorgano, David
  • Campaña Gómez, Irene
  • Sorzano, Carlos Óscar S.
  • Esteban, Mariano
  • Gómez, Carmen E.
  • Guerra, Susana
[Background] Vaccines represent one of the most affordable and efficient tools for controlling infectious diseases; however, the development of efficacious vaccines against complex pathogens remains a major challenge. Adjuvants play a relevant role in enhancing vaccine-induced immune responses. One such molecule is interferon-stimulated gene 15 (ISG15), a key modulator of antiviral immunity that acts both through ISGylation-dependent mechanisms and as a cytokine-like molecule., [Methods] In this study, we assessed the immunostimulatory potential of ISG15 as an adjuvant in Modified Vaccinia virus Ankara (MVA)-based vaccine candidates targeting Zika virus (ZIKV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Early innate responses and immune cell infiltration were analyzed in immunized mice by flow cytometry and cytokine profiling. To elucidate the underlying mechanism of action of ISG15, in vitro co-infection studies were performed in macrophages. Finally, we evaluated the magnitude and functional quality of the elicited antigen-specific cellular immune responses in vivo., [Results] Analysis of early innate responses revealed both platform- and variant-specific effects. ISG15AA preferentially promoted natural killer (NK) cell recruitment at the injection site, whereas ISG15GG enhanced myeloid cell infiltration in draining lymph nodes (DLNs), particularly when delivered via MVA. Moreover, in vitro co-infection of macrophages with MVA-based vaccine vectors and the ISG15AA mutant led to a marked increase in proinflammatory cytokine production, highlighting a dominant role for the extracellular, ISGylation-independent functions of ISG15 in shaping vaccine-induced immunity. Notably, co-infection of ISG15 with MVA-ZIKV and MVA-SARS-CoV-2 vaccine candidates enhanced the magnitude of antigen-specific immune responses in both vaccine models., [Conclusions] ISG15, particularly in its ISGylation-deficient form, acts as a promising immunomodulatory adjuvant for viral vaccines, enhancing both innate and adaptive immune responses. Consistent with previous findings in the context of Human Immunodeficiency virus type 1 (HIV-1) vaccines, this study further supports the potential of ISG15 as an effective adjuvant for vaccines targeting viral infections such as ZIKV and SARS-CoV-2., This research was supported by the Spanish State Research Agency SAF-2017-88089-R, PDC2021-121307-I00, and PID2020-117425RB-C21 to S.G; PID2020-117425RB-C22 to C.E.G; CSIC grant 202120E079 and grant CNS2022-135511, funded by the Spanish Ministry of Science, Innovation and Universities (MCIU)/Spanish Research Agency (AEI)/10.130/501100011033 and by the European Union NextGenerationEU/PRTR to promote the consolidation of research to J.G.-A; CSIC grant 2020E84 to M.E.; Spanish MCIU/AEI/10.13039/501100011033 grant PID2020-114481RB-I00 to J.G.-A. and M.E., and funds from the Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), co-financed with FEDER funds to C.E.G and J.G.-A. This research work was also funded by the European Commission–NextGenerationEU, through CSIC’s Global Health Platform (PTI Salud Global) (to J.G.-A. and M.E). The funders were not involved in the study design, collection, analysis, interpretation of data, writing of this article, or decision to submit it for publication., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Preclinical evaluation of a multi-epitope mRNA vaccine platform for broad and durable SARS-CoV-2 protection

  • Marcos-Villar, Laura
  • Perdiguero, Beatriz
  • Sin, Laura
  • Álvarez, Enrique
  • Flores, Sara
  • Casasnovas, José María
  • Pons, Tirso
  • Sorzano, Carlos Óscar S.
  • Hoyo, Daniel del
  • Lapuhs, Philipp
  • Alonso, María J.
  • Esteban, Mariano
  • Gómez, Carmen E.
Introduction: The emergence of immune-evasive SARS-CoV-2 variants has exposed limitations in the breadth and durability of protection conferred by current Spike-based vaccines, highlighting the need for next-generation approaches targeting conserved viral regions. Here, we describe the design and preclinical evaluation of an optimized multi-epitope vaccine, CoV2-BMEPu. Methods: CoV2-BMEPu was rationally designed using immunological data from SARS-CoV-2 convalescent cohorts, incorporating conserved and immunodominant regions from the Spike (S), Membrane (M) and Nucleocapsid (N) proteins, together with selected receptor-binding domain (RBD) segments associated with broadly neutralizing antibodies. The construct was engineered as a secreted trimeric antigen and delivered as an mRNA vaccine formulated in lipid nanoparticles (LNPs). In vitro expression, innate immune activation, immunogenicity and protective efficacy were evaluated in cell systems and mouse models. Results: mRNA-BMEPu was efficiently expressed in vitro as soluble oligomers and triggered innate immune activation in human macrophages. In C57BL/6 mice, LNP-BMEPu elicited robust binding and neutralizing antibodies against the ancestral virus and antigenically distant Omicron subvariants. Vaccination also induced strong and polyfunctional CD8⁺ T cell and T follicular helper responses that persisted over time. In K18-hACE2 transgenic mice, immunization conferred complete protection against lethal SARS-CoV-2 challenge, with effective control of viral replication and reduced lung inflammation. Discussion: These results support CoV2-BMEPu as a next-generation multi-epitope mRNA vaccine candidate capable of inducing broad, durable and protective immunity against current and emerging SARS-CoV-2 variants. Copyright © 2026 Marcos-Villar, Perdiguero, Sin, Álvarez, Flores, Casasnovas, Pons, Sorzano, del Hoyo, Lapuhs, Alonso, Esteban and Gómez., The author(s) declared that financial support was received for this work and/or its publication. This study was supported by multiple public and private sources. Financial support was provided by La Caixa Banking Foundation (grant CF01-00008), MICIN through the Spanish Research Agency under grants PID2020-117425RB-C21, PID2020-117425RB-C22 and PDC2021-121307-100, as well as by the COVID-19 Fund of the Spanish Health Ministry and Instituto de Salud Carlos III (grant COV20/00151) and CIBERINFEC., Peer reviewed